Acrivon Therapeutics, Inc. (ACRV)
NASDAQ: ACRV · Real-Time Price · USD
1.750
-0.040 (-2.23%)
At close: May 22, 2026, 4:00 PM EDT
1.820
+0.070 (4.00%)
After-hours: May 22, 2026, 7:59 PM EDT

Acrivon Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Selling, General & Admin
22.6124.1225.2121.088.712.47
Research & Development
59.7459.9963.9946.0223.9513.72
Total Operating Expenses
82.3584.1189.267.132.6616.18
Operating Income
-82.35-84.11-89.2-67.1-32.66-16.18
Interest Income
5.476.489.27.04--
Other Non-Operating Income (Expense)
4.75.948.096.391.49-0.12
Total Non-Operating Income (Expense)
10.1712.4217.2913.431.49-0.12
Pretax Income
-72.18-71.7-71.91-53.67-31.17-16.3
Net Income
-77.27-77.91-80.56-60.39-31.17-16.24
Net Income to Common
-77.27-77.91-80.56-60.39-31.17-16.24
Shares Outstanding (Basic)
3939342242
Shares Outstanding (Diluted)
3939342242
Shares Change (YoY)
2.37%13.96%53.05%435.63%136.43%21.70%
EPS (Basic)
-2.00-2.02-2.38-2.74-7.56-9.32
EPS (Diluted)
-2.00-2.02-2.38-2.74-7.56-9.32
Shares Outstanding
38.7531.6531.2322.5221.921.77
Free Cash Flow
-66.29-65.33-68.44-43.93-32.28-14.22
Free Cash Flow Per Share
-1.72-1.70-2.03-1.99-7.83-8.16
EBITDA
-80.93-82.76-88.19-66.57-32.29-16.15
EBIT
-82.35-84.11-89.2-67.1-32.66-16.18
Updated May 13, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q